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Over the last 10 years, advances in molecular biology have
shed new light on the control of cell growth at the genetic
level. Several genes have been identified, called proto-
oncogenes which encode proteins which appear to be
involved in regulating cell division. Abnormalities converting
them to oncogenes appear to be of fundamental importance
in the generation of malignant tumours both in experimental
models and in man. This workshop on oncogenes covered
topics ranging from structural protein chemistry to clinical
applications of oncogene expression.
Oncogenes can be broadly grouped into five classes
according to the intracellular localisation and biochemical
properties of the gene product. These groups are:
(1) Growth factors.
(2) Growth factor receptors, comprising an external
ligand binding domain, a transmembrane section, a
protein-tyrosine kinase domain and a regulatory
domain.
(3) Cytoplasmic protein kinases.
(4) Intracellular signal transducers. Molecules associated
with the cytoplasmic face of the cell membrane
involved in transducing growth at stimulating signals.
(5) Nuclear acting oncogenes.
The topics covered at the workshop are reviewed under these
headings.
Growthfactors
It has been known for some time that the beta-chain of
human platelet derived growth factor (PDGF) and the v-sis
oncogene product of the simian sarcoma virus share
extensive sequence homology. Keiko Funa (Uppsala)
presented evidence that glial cell lines can both produce and
respond to PDGF, provided they are PDGF receptor
positive. Extracts of brain tumours were found to contain
high levels of mRNA encoding either the A or B chain of
PDGF. Some tumours produced both mRNAs but their
expression appeared to be independent. Glial tumours of
fibroblastic morphology contained relatively high levels of
mRNA encoding the PDGF receptor. Contrary to expec-
tations, Dr Funa showed by in vitro hybridisation, using
labelled mRNA for the PDGF A-chain, that the majority of
these appeared to be synthesised in the stromal reaction
surrounding these tumours. Several tumour extracts also
contained other growth factors such as transforming growth
factor a (TGFa). This suggests a role for self-sustaining
autocrine and paracrine secretion in the pathogenesis of
these tumours. None of the tumour cell lines examined had
evidence of gene amplification or rearrangement, and so the
initiating mechanism underlying these changes is unclear - a
recurring theme throughout the workshop.
Growthfactor receptors
There were several presentations on the epidermal growth
factor receptor (EGFR) and its close homologue the c-erbB-2
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gene product. According to data presented by Mark Berger
(Philadelphia) the presence of very high levels of EGFR is a
common finding in squamous cell carcinomas (SCCs) of the
lung, sometimes accompanied by gene amplification though
more usually not. Adeno- and large cell carcinomas were less
frequently EGFR positive and the absolute EGFR level
tended to be lower. None of the small cell tumours examined
were EGFR positive suggesting a separate pathogenesis. In
the few examples examined the EGFR status of both
primary and metastatic deposits was the same for a given
tumour. Several questions were discussed concerning the
significance of supranormal expression of an oncogene -
normal levels of the genes are adequate for cell division.
Does the increased receptor concentration reduce the need
for the normal ligand (e.g. EGF), bypassing the normal
controls? What are the cellular targets for the activated
kinase domains of the receptors? What is the basal kinase
activity? Research in these areas may be expected to yield
new insights into the role of these genes in cancer.
Of more immediate clinical interest are the results
obtained by Adrian Harris' group (Newcastle) on the role of
the EGF receptor in bladder and breast cancer. The recent
finding that EGFR status is the best single prognostic
indicator in breast cancer raises the possibility of more
precise tailoring of treatment to patients, restricting toxic
drugs to poor prognosis patients. Furthermore, unlike
oestrogen receptor (ER) status where ER positive and
negative patients have different short-term but similar long-
term survival, EGFR status appears to identify distinct
prognostic groups. EGFR status also correlates with
prognosis in bladder cancer. Of great significance is the
observation that EGFR positive Ta tumours were highly
likely to progress to invasive cancer whereas none of the
EGFR negative tumours did, again identifying a group
requiring more aggressive management.
Results were presented from two groups (Roel Nusse,
Netherlands and Bill Gullick, London) concerning the
expression of c-erbB-2 in human breast cancer. The c-erbB-2
gene product is related in structure to the EGF receptor.
This gene in rats, termed the nell gene, can be activated by a
point mutation to a dominantly transforming analogue. The
normal human c-erbB-2 gene can also transform mouse
NIH-3T3 cells when expressed at elevated levels. Both
groups obtained similar results showing that frequent
amplification (20-30% of cases) of the c-erbB-2 gene in
primary breast carcinomas was invariably associated with
elevated expression of the protein, assessed by immunohisto-
logical staining or western blotting of tumour extracts. Dr
Gullick showed some results using immunohistological
staining examining the expression of the gene in normal
human tissue. Discussion ensued concerning the prognostic
significance of this genetic abnormality and it was agreed
that many more cases needed to be examined to assess its
true value.
Dr Roel Nusse also presented results in which he showed
that the mouse int-i gene, activated to an oncogene by
insertional mutagenesis, is identical to the drosophila
segment polarity gene wingless. This discovery suggested that
the int-i gene product may function in a similar way to the
wingless gene which appears to act as a morphogenic signal
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in cell-cell communication. These results complement others
reported recently which suggest that the growth regulatory
oncogene system (or molecules related in structure) may have
some involvement in embryogenesis or tissue pattern
formation.
Tyrosine kinases
It has been known for some time that the 9/22 reciprocal
translocation of Philadelphia positive (Ph+) chronic myeloid
leukaemia (CML) produces a hybrid bcr-abl gene product
with enhanced kinase activity compared with the c-abl gene
product. Evidence for a similar molecular abnormality in
haemotologically typical Ph-, CML and Ph+ acute
leukaemia resulting in c-abl fusion proteins with kinase
activity was presented by Dr Weidermann (London),
suggesting a common underlying molecular mechanism for
all these diseases.
Intracellular messengers
The main interest in this area at the workshop centred on
the intracellular functions of the p21 ras protein. Drs Furth
(New York) and McCormick (San Fransisco) presented
evidence suggesting a non-proliferative signal transduction
role based on the GTPase activity of p21 and modulated by
an as yet uncharacterised protein. Dr Furth discussed the
production of monoclonal antibodies which discriminate
between the three p21-ras proteins in western blots. A
monoclonal antibody reactive with all three ras proteins was
used to determine the expression in a variety of human
tissues by immunohistological staining. Tissues that stained
appreciably included epithelial cells, brain, kidney, mammary
gland epithelia, thyroid and pancreas. The effect of specific
mutations on p21 GTP-binding was also discussed. These
papers gave new insights into how oncogenes function in
both normal and abnormal cells.
Nuclear oncogenes
The precise functions of the nuclear-acting oncogenes such
as the myc genes remains unclear. Both the c- and N-
myc code for proteins with nuclear localisation and short
half-lives. Immunocytochemical data presented by Cathy
Waters (Cambridge) showed the proteins to have precise
nuclear localisation and demonstrated a technique of
possible value in both clinical and research laboratories as it
preserves the normal cellular architecture. The amplification
of N-myc in neuroblastomas is known to correlate with
prognosis, again the underlying mechanisms for the
abnormality and its role in pathogenesis are poorly
understood.
A variety of presentations dealt with more general aspects
of oncogene expression and carcinogenesis. Alan Balmain
(Glasgow), using the mouse skin SCC model, showed that
different carcinogens produced tumours by apparently
distinct molecular mechanisms not necessarily involving
known oncogenes. Growth factors appeared to play an
important role in tumour promotion echoing Dr Funa's data
on glial tumours. Desmond Carney (Dublin) presented evi-
dence based on cell culture techniques supporting a common
stem cell origin for the various lung carcinomas. Again,
abnormalities in oncogene expression were not prominent.
Conclusions
The overall impression generated by the workshop was that
the study of oncogene abnormalities has generated a lot of
interesting associations but, with a few exceptions such as
the EGFR studies little of direct relevance to clinical
medicine - a situation analogous to that seen with HLA
associations and disease. Apart from the bcr-abl/CML
association, none of the molecular abnormalities seem to be
obligatory for carcinogenesis. Could oncogene abnormalities
just be epiphenomena or can the apparent gaps be filled by
alternative oncogenes yet to be discovered? The area holds
fascinating promise for future research.